The study deals with theoretical and experimental structural analysis via mass spectrometry and nuclear magnetic resonance of complexes of competitively interacting oligopeptides with Cu(I/II) and Zn(II) ions; thus, producing innovative species as prospective candidate therapeutics governing aggregation and catalyzed reactive oxygen reactions of the Alzheimer’s disease. There is peptide coordination with Cu(I/II) ions; thus, preventing Cu(II)-amyloidal-beta (Ab) complex formation as a prospective therapeutic approach. It improves therapeutics-like property of oligopeptides and tackles metal ion selectivity. Further, ologopeptides appear selective toward Cu(II)-ion in presence of Zn(II)-one. The theme is crucial for efficacious management of neuromodulated processes, because not only Alzheimer’s disease, but also neurodegenerative disorders exhibit similar protein aggregation reactions. An in-depth understanding of interactions of oligopeptides, Cu(I/II), and Zn(II)-ions; thus, preventing Cu(II)-Ab formation improves medication administration. Scarce data on Cu(II)-oligopeptide therapeutics occur. Proteins are key macromolecules in Alzheimer’s disease pathology. This research achieves integrated knowledge of metalloproteins involved in Alzheimer’s disease and based on Cu(II)-peptide complexes. It challenges both the fundamental and applied science. In vivo processes via mimic of biomacromolecular structures entail synthetic oligopeptides joined with transition metal ions. Ternary metal-peptide complexes mimic active sites. Further, Cu(I/II)-Aβ interaction with molecular oxygen is implicated into fibrillization of Aβ-peptides as a hallmark of Alzheimer’s disease pathology. Data on Cu(I/II)-Aβ-peptide-O2 intermediates crucially fill the gap of knowledge of hCu(I/II) ions modulated Aβ-peptides reactions. In addition to aforementioned robust methods for structural analysis of chemicals, there are also utilized high accuracy approaches to quantum chemistry.